Prof Dr Christoph Hiemke is affiliated with the Department of Psychiatry and Psychotherapy and the Institute of Clinical Chemistry and Laboratory Medicine at the University Medical Center of Mainz, Germany, and is a member of the AGNP Task Force on Therapeutic Drug Monitoring. His publications from 2014 to 2023 focus on therapeutic drug monitoring in psychiatric conditions, including depression, schizophrenia, and schizoaffective disorders. His work addresses blood concentration reference ranges for antipsychotics such as olanzapine, dosing strategies for antidepressants like duloxetine and venlafaxine, and optimizing antipsychotic treatment in clinical practice.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
